Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Jaguar Health, Inc. | a17-20268_1ex99d2.htm |
| EX-99.1 - EX-99.1 - Jaguar Health, Inc. | a17-20268_1ex99d1.htm |
| 8-K - 8-K - Jaguar Health, Inc. | a17-20268_18k.htm |
Exhibit 23.1
Consent of Independent Auditors
Napo Pharmaceuticals, Inc.
San Francisco, California
We hereby consent to the incorporation by reference in the Form 8-K of our report dated March 24, 2017, except for Note 15-Additional Subsequent Events, the first and second paragraphs as to which the date is March 31, 2017, the third paragraph as to which the date is June 27, 2017 and the fourth paragraph as to which the date is July 31, 2017 (the report contains an explanatory paragraph regarding Napo Pharmaceuticals, Inc.’s ability to continue as a going concern) with respect to the consolidated financial statements of Napo Pharmaceuticals, Inc., appearing in the Form 8-K/A of Jaguar Health, Inc. filed on August 4, 2017.
|
/s/ Macias Gini & O’Connell LLP |
|
|
|
San Francisco, California |
|
August 28, 2017 |